VivaTome, an optical microscope accessory from Carl Zeiss and Aurox Ltd., addresses the problem of unwanted blurred information being included with the primary in-focus information from.
This month, I am pleased to share with you some features that are in our magazine, and some that are not. Editors are frequently frustrated by the physical limitations of the printed page.
In late September, the U.S. Food and Drug Administration issued a final rule that clarifies what safety information must be reported during clinical trials of investigational drugs and biologics.
Many articles describe assays that work in multi-well plates, but without the technology to read the results these assays are of limited benefit to the drug discovery and development process.
Harvard Apparatus offers the 192-Well DispoEquilibrium DIALYZERS that analyze up to 96 samples simultaneously on disposable dialysis plates.
Affymetrix has launched the GeneAtlas System to make Affymetrix microarrays accessible to all life science researchers.
ImmunoGen, Inc. announced that it has entered into a collaboration agreement with Novartis to discover and develop targeted anticancer therapeutics using antibodies to several antigen targets to be named by Novartis.
Exelixis, Inc. has entered into two collaboration agreements with Bristol-Myers Squibb Company. Under the first agreement, Exelixis will grant to Bristol-Myers Squibb an exclusive license to its small-molecule TGR5 agonist program including backups.
A new lexicon that revises and unifies the definition of Alzheimer's disease to include recent developments in the field, in which biomarkers are the key to diagnosis, has been proposed by an international group of Alzheimer's disease experts.
Delivering short strands of RNA into cells has become a popular research area because of its potential therapeutic applications, but until now, how to deliver them into targeted cells in a living organism has been an obstacle.
Allon Therapeutics Inc.'s lead candidate, davunetide, met its primary trial endpoint of safety and tolerability in patients with progressive supranuclear palsy and other types of frontotemporal dementia.
Federal regulators want additional clinical studies of a fibromyalgia drug candidate from Jazz Pharmaceuticals. New clinical trials could take years to complete, delaying approval for the drug JZP-6 and significantly increase expenses for Jazz.
Abbott Laboratories said it will withdraw its diet pill Meridia in the U.S. and Canada, after coming under pressure from health regulators who say the drug increases the risk of heart attack and stroke in patients with a history of heart disease.
Sanofi-Aventis SA, the world's fourth-biggest drugmaker, said it is eliminating 1,700 jobs in its U.S. pharmaceutical business in a restructuring triggered by growing generic competition and other factors.
Fifteen academic medical centers, research institutes, and major pharmaceutical companies are collaborating to enhance the speed and quality of clinical trials by harnessing patient data emerging from the coming widespread adoption of electronic health records.